Project Grant R37CA303874
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $483K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $734,435.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The key objectives are to define the molecular mechanisms underlying BH3 mimetic resistance in AML and evaluate whether targeting the ADSS2 enzyme,...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Beckman Research Institute of the City of Hope to investigate the role of IL-6/STAT3 signaling in the progression and metastasis of CIC-DUX4 fusion-positive sarcomas. The $593,028 award, effective April 3, 2025 through March 31, 2030, will fund studies to determine whether targeting the IL-6/STAT3 pathway can block tumor growth, metastasis, and immunosuppression...
- This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
- The University of Michigan was awarded a $500,719 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to study the mechanisms driving genetic subtypes of B-cell acute lymphoblastic leukemia (B-ALL). The project aims to provide direct evidence that the activation of GGAA repeat enhancers is a causative mechanism for the gene expression signature of the rare but aggressive ETV6-RUNX1-like B-ALL subtype. The research will use innovative methods...
- This $738,698 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope supports research on a novel anti-CD38 targeted alpha therapy (TAT) combined with total marrow irradiation (TMLI) for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The goal is to develop an innovative, organ-sparing radiotherapy approach that can safely escalate the radiation...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...